Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) Inventory Average (2016 - 2025)

Historic Inventory Average for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $6.6 billion.

  • Astrazeneca's Inventory Average rose 2009.13% to $6.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.6 billion, marking a year-over-year increase of 2009.13%. This contributed to the annual value of $5.9 billion for FY2025, which is 1057.69% up from last year.
  • Astrazeneca's Inventory Average amounted to $6.6 billion in Q4 2025, which was up 2009.13% from $6.5 billion recorded in Q3 2025.
  • Astrazeneca's Inventory Average's 5-year high stood at $9.8 billion during Q4 2021, with a 5-year trough of $3.7 billion in Q1 2021.
  • Its 5-year average for Inventory Average is $5.9 billion, with a median of $5.5 billion in 2024.
  • In the last 5 years, Astrazeneca's Inventory Average surged by 18821.38% in 2021 and then plummeted by 4988.98% in 2022.
  • Over the past 5 years, Astrazeneca's Inventory Average (Quarter) stood at $9.8 billion in 2021, then tumbled by 49.89% to $4.9 billion in 2022, then increased by 9.6% to $5.4 billion in 2023, then increased by 2.18% to $5.5 billion in 2024, then rose by 20.09% to $6.6 billion in 2025.
  • Its last three reported values are $6.6 billion in Q4 2025, $6.5 billion for Q3 2025, and $6.2 billion during Q2 2025.